Regenerative Medical Technology Group Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.0M | $2.6M | $1.6M | $1.2M | $983.3K | $1.4M | $1.5M | $986.3K |
| Cost of Revenue | $1.4M | $872.9K | $792.4K | $679.0K | $397.7K | $420.4K | $530.6K | $239.2K |
| Gross Profit | $2.6M | $1.8M | $779.7K | $501.6K | $585.6K | $943.9K | $980.2K | $747.1K |
| Gross Margin | 64.1% | 66.9% | 49.6% | 42.5% | 59.6% | 69.2% | 64.9% | 75.7% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $619.2K | $475.8K | $389.3K | $277.7K | $207.4K | $245.6K | $113.1K | $264.1K |
| Operating Income | $566.0K | $229.8K | $-306.3K | $-445.8K | $-250.1K | $135.0K | $380.6K | $19.6K |
| Operating Margin | 14.1% | 8.7% | -19.5% | -37.8% | -25.4% | 9.9% | 25.2% | 2.0% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-2.9M | $-876.3K | $-1.3M | $-4.4M | $-1.4M | $-760.0K | $-638.2K | $-887.1K |
| Net Margin | -72.2% | -33.2% | -79.8% | -368.8% | -146.8% | -55.7% | -42.2% | -89.9% |
| EPS (Basic) | $-0.22 | $-0.07 | $-0.09 | $-0.35 | $-0.12 | $-0.06 | $-0.04 | $-0.07 |
| EPS (Diluted) | $-0.22 | $-0.07 | $-0.09 | $-0.35 | $-0.12 | $-0.06 | $-0.04 | $-0.07 |
| Shares Outstanding (Basic) | 13.2M | 13.1M | 12.6M | 12.5M | 12.5M | 12.5M | 12.5M | 12.5M |
| Shares Outstanding (Diluted) | 13.2M | 13.1M | 12.6M | 12.5M | 12.5M | 12.5M | 12.5M | 12.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |